A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database
Abstract The impact of bisphosphonates on cardiac arrhythmia has always been controversial. We aimed to evaluate the risk of bisphosphonates (BPs) on arrhythmia and to characterize the main features of BP-induced arrhythmia by data mining the FDA adverse event Reporting System (FAERS). From the firs...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-00900-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399748092493824 |
|---|---|
| author | Feifei Wang Guishui Xu Qian Wang Xinan Wu |
| author_facet | Feifei Wang Guishui Xu Qian Wang Xinan Wu |
| author_sort | Feifei Wang |
| collection | DOAJ |
| description | Abstract The impact of bisphosphonates on cardiac arrhythmia has always been controversial. We aimed to evaluate the risk of bisphosphonates (BPs) on arrhythmia and to characterize the main features of BP-induced arrhythmia by data mining the FDA adverse event Reporting System (FAERS). From the first quarter of 2016 to the second quarter of 2022, reports for BP-related cardiac arrhythmia adverse event (AE) from FAERS database were analyzed in this study. The reporting odds ratio (ROR) and information components (IC) were used to identify disproportionate reporting of BP-related cardiac arrhythmias. We identified a total of 2377 BP-related cardiac arrhythmias cases which appeared to influence more women (61.88%) than men (28.02%), with a median age of 70 (interquartile range [IQR] 59–78) years. Compared with the full database, BPs were detected with pharmacovigilance of cardiac arrhythmias (ROR025 = 1.43, [1.39–1.47]). All studied bisphosphonates except ibandronate sodium and clodronate disodium were correlated with the reporting frequency of cardiac arrhythmia (HLGT), with ROR ranging from 1.28 with pamidronate disodium to 11.08 with etidronate disodium. The spectrum of arrhythmias induced by BPs differed among therapeutic regimens. There were significant differences in the onset time among BP regimens. Bisphosphonates use is associated with adverse cardiac arrhythmias, with the exception of ibandronate sodium and clodronate disodium. Our data support differential effects of BPs on cardiac arrhythmias. |
| format | Article |
| id | doaj-art-aac20f9eaf6646e2a42bd0abed1af35b |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-aac20f9eaf6646e2a42bd0abed1af35b2025-08-20T03:38:15ZengNature PortfolioScientific Reports2045-23222025-07-011511810.1038/s41598-025-00900-yA disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS databaseFeifei Wang0Guishui Xu1Qian Wang2Xinan Wu3Department of Pharmacy, Hefei BOE HospitalOrthopaedic Department of the First People’s Hospital of AnqingDepartment of Pharmacy, Hefei BOE HospitalDepartment of Pharmacy, Hefei BOE HospitalAbstract The impact of bisphosphonates on cardiac arrhythmia has always been controversial. We aimed to evaluate the risk of bisphosphonates (BPs) on arrhythmia and to characterize the main features of BP-induced arrhythmia by data mining the FDA adverse event Reporting System (FAERS). From the first quarter of 2016 to the second quarter of 2022, reports for BP-related cardiac arrhythmia adverse event (AE) from FAERS database were analyzed in this study. The reporting odds ratio (ROR) and information components (IC) were used to identify disproportionate reporting of BP-related cardiac arrhythmias. We identified a total of 2377 BP-related cardiac arrhythmias cases which appeared to influence more women (61.88%) than men (28.02%), with a median age of 70 (interquartile range [IQR] 59–78) years. Compared with the full database, BPs were detected with pharmacovigilance of cardiac arrhythmias (ROR025 = 1.43, [1.39–1.47]). All studied bisphosphonates except ibandronate sodium and clodronate disodium were correlated with the reporting frequency of cardiac arrhythmia (HLGT), with ROR ranging from 1.28 with pamidronate disodium to 11.08 with etidronate disodium. The spectrum of arrhythmias induced by BPs differed among therapeutic regimens. There were significant differences in the onset time among BP regimens. Bisphosphonates use is associated with adverse cardiac arrhythmias, with the exception of ibandronate sodium and clodronate disodium. Our data support differential effects of BPs on cardiac arrhythmias.https://doi.org/10.1038/s41598-025-00900-yBisphosphonatesCardiac arrhythmiasAdverse eventFAERSPharmacovigilance |
| spellingShingle | Feifei Wang Guishui Xu Qian Wang Xinan Wu A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database Scientific Reports Bisphosphonates Cardiac arrhythmias Adverse event FAERS Pharmacovigilance |
| title | A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database |
| title_full | A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database |
| title_fullStr | A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database |
| title_full_unstemmed | A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database |
| title_short | A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database |
| title_sort | disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the faers database |
| topic | Bisphosphonates Cardiac arrhythmias Adverse event FAERS Pharmacovigilance |
| url | https://doi.org/10.1038/s41598-025-00900-y |
| work_keys_str_mv | AT feifeiwang adisproportionalityanalysisofcardiacarrhythmiaassociatedwithbisphosphonatesbasedonthefaersdatabase AT guishuixu adisproportionalityanalysisofcardiacarrhythmiaassociatedwithbisphosphonatesbasedonthefaersdatabase AT qianwang adisproportionalityanalysisofcardiacarrhythmiaassociatedwithbisphosphonatesbasedonthefaersdatabase AT xinanwu adisproportionalityanalysisofcardiacarrhythmiaassociatedwithbisphosphonatesbasedonthefaersdatabase AT feifeiwang disproportionalityanalysisofcardiacarrhythmiaassociatedwithbisphosphonatesbasedonthefaersdatabase AT guishuixu disproportionalityanalysisofcardiacarrhythmiaassociatedwithbisphosphonatesbasedonthefaersdatabase AT qianwang disproportionalityanalysisofcardiacarrhythmiaassociatedwithbisphosphonatesbasedonthefaersdatabase AT xinanwu disproportionalityanalysisofcardiacarrhythmiaassociatedwithbisphosphonatesbasedonthefaersdatabase |